###begin article-title 0
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 302 309 302 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 393 398 <span type="species:ncbi:9606">women</span>
The host immunogenetic background plays an important role in the development of breast cancer. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a molecule expressed predominantly on activated T cells and is important during the down-regulation of T-cell activation. To evaluate the potential influences of CTLA-4 gene polymorphisms on breast cancer risk, a case-control study was conducted in Han women of Northeast China.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 13 20 13 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
We genotyped CTLA-4 variants (-1661 G/A, -658 T/C, -318 T/C, +49 G/A and CT60 G/A) to tag all common haplotypes (>/= 1% frequency) in 117 Chinese breast cancer cases and 148 age/sex matched healthy individuals. Genotypes were determined by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. Data was analyzed using the Chi-square test and Haploview software.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 17 24 17 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 133 135 133 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 172 174 172 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 211 213 211 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 341 343 341 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 466 468 466 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 490 497 490 497 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 573 575 573 575 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 612 614 612 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 761 763 761 763 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 773 775 773 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 791 793 791 793 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 106 114 <span type="species:ncbi:9606">patients</span>
###xml 456 464 <span type="species:ncbi:9606">patients</span>
###xml 563 571 <span type="species:ncbi:9606">patients</span>
The frequency of CTLA-4 -1661G allele, -318T allele and CT60G allele carriers was significantly higher in patients than in controls (P = 0.0057, OR 1.91, 95% CI 1.21-3.02; P = 0.0031, OR 2.39, 95% CI 1.34-4.27; P = 0.023, OR 1.52, 95% CI 1.06-2.17, respectively). The -658T allele carrier frequency was significantly lower than in controls (P = 0.0000082, OR 0.17, 95% CI 0.08-0.37), whereas the +49A allele was significantly associated with tumor size in patients (P = 0.0033). Two common CTLA-4 haplotypes, ATCGA and ATCAG, were higher in healthy controls than patients (P = 0.0026, OR 0.17, 95% CI 0.05-0.54; P = 0.034, OR 0.12, 95% CI 0.02-0.92, respectively). A strong association was observed between tumor size and the ACCAA, ACCAG and ACCGA haplotypes (P = 0.0032, P = 0.0000031 and P = 0.017).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 48 55 48 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 148 153 <span type="species:ncbi:9606">women</span>
These results suggest that polymorphisms of the CTLA-4 gene may modify individual susceptibility to and progression of breast cancer in Chinese Han women.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 591 592 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 47 52 <span type="species:ncbi:9606">women</span>
Breast cancer is the most common malignancy in women worldwide and its rate is increasing in both developed and developing countries. The etiology of breast cancer is complicated and not completely known, but recent studies have focused on the role of the immune system. During the development of breast cancer, innate and adaptive responses are carefully orchestrated through soluble and membrane-bound regulators, resulting in the deployment of the most suitable effectors for controlling the growth of tumor. However, the biological importance of these responses is not fully understood [1]. The most significant anti-tumor response is cell-mediated and involves T lymphocytes and natural killer (NK) cells. Thus, the variants of those genes that regulate the activation and proliferation of T lymphocytes and NK cells may affect the risk of breast cancer.
###end p 11
###begin p 12
###xml 262 263 262 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 264 265 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 329 330 329 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 354 355 354 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 441 448 441 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 640 647 640 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 660 661 660 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 747 754 747 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 973 980 973 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 1069 1076 1069 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 1144 1145 1144 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1274 1275 1274 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1361 1368 1361 1368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 1496 1497 1496 1497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1498 1499 1498 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1500 1502 1500 1502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1543 1545 1543 1545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1546 1548 1546 1548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1618 1625 1618 1625 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 2055 2062 2055 2062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 2120 2122 2120 2122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 2123 2125 2123 2125 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 2175 2182 2175 2182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 2393 2400 2393 2400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 372 376 <span type="species:ncbi:10090">mice</span>
###xml 1756 1764 <span type="species:ncbi:9606">patients</span>
###xml 2089 2097 <span type="species:ncbi:9606">patients</span>
###xml 2254 2262 <span type="species:ncbi:9606">patients</span>
Cytotoxic T-lymphocyte antigen-4 (CTLA-4), encoded by a gene on chromosome 2q33, is a receptor expressed by activated T lymphocytes. It interacts with the B-7 cell surface molecule on antigen-presenting cells and inhibits T cell activation and clonal expansion [2,3]. CTLA-4 blockade leads to enhancement of the immune response [4], rejection of tumors [5], or even cures mice of tumors when used in combination with tumor vaccines [6]. The CTLA-4 gene consists of four exons and has been shown to be an important candidate gene for T cell-mediated diseases. More than 100 single-nucleotide polymorphisms (SNPs) have been identified in the CTLA-4 gene region [7]. Several important polymorphic sites have been reported in the entire region of the CTLA-4 gene. Among these variants, only A/G dimorphism at position +49 in exon 1 causes an amino acid exchange (threonine to alanine) in the peptide leader sequence of the CTLA-4 protein. Significantly increased expression of CTLA-4 mRNA and protein have been shown in individuals carrying thymine at position -318 of the CTLA-4 promoter and those homozygous for adenine at position 49 in exon 1 [8]. Ueda et al. reported that the G allele at the CT60 position was associated with a 50% decrease in the soluble CTLA-4 isoform [7]. Previous studies have extensively examined the association of polymorphisms within CTLA-4 with autoimmune diseases including Graves' disease, type I diabetes, systemic lupus erythematosus, and Hashimoto's thyroiditis [7,9-11], as well as malignancy susceptibility [12-15]. Some reports imply that the distribution of certain alleles of the CTLA-4 gene in cancer is contrary to autoimmune diseases: that is, those alleles that confer susceptibility to autoimmunity are sparse in patients with cancer or associated with good prognosis of the cancer. A recent report in an Iranian population showed that there was an association of an AA genotype at +49A/G with susceptibility to breast cancer and no significant differences in the promoter region (-1661 A/G and -318 C/T) of the CTLA-4 gene polymorphisms between patients and healthy controls [12,13]. To evaluate whether these polymorphisms of the CTLA-4 gene were likely to be of importance in Chinese breast cancer, we typed patients and controls for five of these important SNPs in the Chinese Han population of Northeast China. The five polymorphic sites of the CTLA-4 gene included three in the promoter region (-1661 G/A, -658 T/C, -318 T/C), one in exon 1 (+49 G/A) and one in 3'-UTR (CT60 G/A).
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Subjects
###end title 14
###begin p 15
###xml 447 448 445 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 52 57 <span type="species:ncbi:9606">women</span>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
###xml 353 361 <span type="species:ncbi:9606">patients</span>
###xml 583 588 <span type="species:ncbi:9606">women</span>
###xml 749 757 <span type="species:ncbi:9606">patients</span>
The study group consisted of a total of 117 Chinese women with breast cancer, ranging in age from 30 to 73 years (mean age at diagnosis 48.7 +/- 9.5 years). These patients came from the Department of Abdominal Surgery (The Third Affiliated Hospital of Harbin Medical University). Breast cancer was diagnosed from surgical and pathological symptoms. The patients' pathological and clinical information were obtained from their medical files (Table 1). The control group came from healthy blood donors consisting of 148 unrelated age (mean age at sampling 46.3 +/- 17.0 years) matched women who were randomly selected from community volunteers in the same district, without a history of personal and familial malignancy and autoimmune disorders. Both patients and healthy controls originated from the Heilongjiang Province of China between September 2005 and June 2006. Samples were obtained from subjects after they had provided written informed consent.
###end p 15
###begin p 16
###xml 44 52 <span type="species:ncbi:9606">patients</span>
Clinicopathologic features of breast cancer patients (n = 117)
###end p 16
###begin p 17
Abbreviations: IDC, infiltrative ductal carcinoma; MC, medullary carcinoma; LN, lymph node; TZ, tumor size.
###end p 17
###begin title 18
DNA extraction and genotyping
###end title 18
###begin p 19
###xml 507 508 505 506 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 679 686 674 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 753 754 748 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 993 994 988 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1060 1062 1055 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
Genomic DNA was extracted from 5 ml frozen whole blood using the DNA Extraction Kit (Qiagen, Germany) according to the manufacturer's protocol. A polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay was used to detect dimorphism of -1661 G/A, -658 T/C, -318 T/C, +49 G/A and CT60 G/A. The polymorphic region was amplified by PCR with a T-Gradient Thermoblock PCR System iometra, Germany) in a 25 mul reaction solution containing 0.3 mug genomic DNA, 1x PCR buffer, 0.3 mM MgCl2, 0.2 mM dNTPs, 2 U Taq DNA polymerase (Takara, Japan) and 0.1 mumol of each primer (Shenggong, China). SNPs were selected to tag all common (>/= 1% population frequency) CTLA-4 haplotypes. Genotyping primers and PCR programs are shown in Table 2. PCR products were digested overnight with restriction enzymes (NEB, UK) according to the manufacturer's protocol and analyzed by 2% agarose gel electrophoresis. Restriction enzymes and the length of digested fragments are shown in Table 3. This methodology was robust with a 97.8% genotype success rate [16].
###end p 19
###begin p 20
Primers and PCR programs for CTLA-4 PCR-RFLP genotyping
###end p 20
###begin p 21
Restriction enzymes and length of digested fragments
###end p 21
###begin title 22
Statistical analysis
###end title 22
###begin p 23
###xml 146 148 146 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 348 350 348 350 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 606 608 606 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P-</italic>
We tested for Hardy-Weinberg equilibrium (HWE) among cases and controls separately. SNPs were excluded from the analysis if they were out of HWE (P < 0.05), had a minor allele frequency of less than 5%, or had more than 25% missing data. The allele and genotype frequencies were obtained by direct counting. Statistical significance was defined as P < 0.05. We used Haploview 3.2 software to reconstruct haplotypes and estimate haplotype frequencies in the unrelated cases and controls. In order to obtain a measure of significance corrected for multiple testing bias we ran 10,000 permutations to compute P-values using the Haploview program. Comparisons of the distributions of the allele, genotype and haplotype frequencies were performed using the chi-square test. The relative risk associated with rare alleles was estimated as an odds ratio (OR) with a 95% confidence interval (CI).
###end p 23
###begin title 24
Results
###end title 24
###begin title 25
Genotype and allele frequencies
###end title 25
###begin p 26
###xml 43 50 43 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 136 137 136 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 189 191 189 191 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 487 488 487 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 495 502 495 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 594 596 594 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 633 635 633 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 677 684 677 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 805 807 805 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 844 846 844 846 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 883 885 883 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1006 1008 1006 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1056 1057 1056 1057 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 1148 1150 1148 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1197 1198 1197 1198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 1343 1345 1343 1345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1776 1778 1776 1778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1795 1797 1795 1797 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1959 1961 1959 1961 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 86 94 <span type="species:ncbi:9606">patients</span>
###xml 567 575 <span type="species:ncbi:9606">patients</span>
###xml 778 786 <span type="species:ncbi:9606">patients</span>
###xml 1121 1129 <span type="species:ncbi:9606">patients</span>
###xml 1503 1511 <span type="species:ncbi:9606">patients</span>
The genotype and allele frequencies of the CTLA-4 gene polymorphisms in breast cancer patients and healthy controls are shown in Tables 4 and 5. All of the five SNPs genotyped were in HWE (P > 0.05) in our case and control cohort. The minor allele frequencies were more than 5% and all of the missing data were less than 25%. When the genotype frequencies were compared between cases and controls, -1661, -658 and -318 SNPs showed statistically significant association (Details in Table 4). The CTLA-4 -1661 AA genotype and -318 CC genotype frequencies were lower in patients than in controls (P = 0.0022, OR 0.44, 95% CI 0.26-0.74; P = 0.0018, OR 0.37, 95% CI 0.20-0.69). The CTLA-4 -1661G allele, -318T allele and CT60G allele carrier frequencies were significantly higher in patients than in controls (P = 0.0057, OR 1.91, 95% CI 1.21-3.02; P = 0.0031, OR 2.39, 95% CI 1.34-4.27; P = 0.023, OR 1.52, 95% CI 1.06-2.17, respectively). In contrast, the -658 CC genotype frequency was significantly higher (P = 0.0000027, OR 6.92, 95% CI 3.08-15.52) (Table 4) and the T allele carrier frequency was significantly lower in patients than in controls (P = 0.0000082, OR 0.17, 95% CI 0.08-0.37) (Table 5). After highly conservative correction for multiple testing, significant association was only observed for the -1661G, -658T and -318T alleles (P = 0.031, 0.00010 and 0.017, respectively). Statistical analysis revealed no significant differences in the genotype and allele frequencies in +49 G/A between patients and healthy controls. Analysis of association between genotypes and predictive factors of breast cancer revealed no association between genotypes at these five SNP sites and lymph node metastasis. Tumor size was significantly different between carriers of the AA (P = 0.026) and GG (P = 0.0018) genotypes at position +49 G/A in comparison to other genotypes. In addition, we found a significant association between the +49A allele and tumor size (P = 0.0033).
###end p 26
###begin p 27
###xml 62 70 <span type="species:ncbi:9606">patients</span>
Genotype frequencies of CTLA-4 polymorphisms in breast cancer patients and healthy controls
###end p 27
###begin p 28
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink"># </sup>
###xml 2 10 <span type="species:ncbi:9606">patients</span>
# patients (n = 109), missing (n = 8); controls (n = 148), missing (n = 0)
###end p 28
###begin p 29
###xml 0 7 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224; </sup>
###xml 7 15 <span type="species:ncbi:9606">patients</span>
dagger patients (n = 115), missing (n = 2); controls (n = 145), missing (n = 3)
###end p 29
###begin p 30
###xml 54 62 <span type="species:ncbi:9606">patients</span>
CTLA-4 allele counts and frequencies in breast cancer patients and healthy controls
###end p 30
###begin p 31
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink"># </sup>
###xml 2 10 <span type="species:ncbi:9606">patients</span>
# patients (n = 109), missing (n = 8); controls (n = 148), missing (n = 0)
###end p 31
###begin p 32
###xml 0 7 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224; </sup>
###xml 7 15 <span type="species:ncbi:9606">patients</span>
dagger patients (n = 115), missing (n = 2); controls (n = 145), missing (n = 3)
###end p 32
###begin p 33
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>a</italic></sup>
###xml 1 3 1 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 12 13 12 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink">b</italic>
###xml 12 13 12 13 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>b</italic></sup>
###xml 13 15 13 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 29 30 29 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c</italic>
###xml 29 30 29 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>c</italic></sup>
###xml 30 32 30 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 61 62 61 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
aP = 0.031, bP = 0.00010 and cP = 0.017 after correcting the P-value for multiple testing by Haploview program using 10,000 permutations.
###end p 33
###begin title 34
Haplotypes analysis
###end title 34
###begin p 35
###xml 54 55 52 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T6">6</xref>
###xml 472 474 470 472 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 487 489 485 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 532 533 530 531 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 703 705 701 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 98 106 <span type="species:ncbi:9606">patients</span>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
###xml 431 439 <span type="species:ncbi:9606">patients</span>
Haplotypes with frequencies >/= 1% are shown in Table 6. The most frequent haplotypes observed in patients and controls were haplotype ACCAG (-1661A, -658C, -318C, +49A, CT60G) (25.5%) and ACCGA (27.1%). However, statistical analysis did not reveal significant differences in the frequencies of these two haplotypes between patients and healthy controls. The frequencies of haplotypes, ATCGA and ATCAG, were significantly lower in patients compared with healthy controls (P = 0.0026 and P = 0.034, respectively). However, after the P-value was corrected for multiple testing using the permutation option available in Haploview 3.2 software, a significant association was only found for haplotype ATCGA (P = 0.012, OR 0.17, 95% CI 0.05-0.54).
###end p 35
###begin p 36
###xml 46 54 <span type="species:ncbi:9606">patients</span>
CTLA-4 haplotype frequencies in breast cancer patients and healthy controls
###end p 36
###begin p 37
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a</italic>
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>a</italic></sup>
###xml 1 3 1 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 32 33 32 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
aP = 0.012 after correcting the P-value for multiple testing by Haploview program using 10,000 permutations.
###end p 37
###begin p 38
###xml 277 279 277 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 289 291 289 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 307 309 307 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 181 189 <span type="species:ncbi:9606">patients</span>
Association with tumor prognostic or predictive factors was also observed with certain haplotypes. Although there was no association between haplotypes and lymph node metastasis in patients, we found strong association of tumor size with the ACCAA, ACCAG and ACCGA haplotypes (P = 0.0032, P = 0.0000031 and P = 0.017, respectively).
###end p 38
###begin title 39
Discussion
###end title 39
###begin p 40
###xml 183 185 183 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 417 419 417 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 596 603 596 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 686 688 686 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 689 691 689 691 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 878 885 878 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 944 949 <span type="species:ncbi:9606">women</span>
The determination of genetic polymorphisms is a new means to study the etiology of polygenetic disorders with complex inheritance patterns, such as cancer, diabetes and hypertension [17]. CTLA-4 exerts distinct independent effects during different phases of T cell responses, including setting the threshold for T cell activation, suppression of T cell proliferation, and induction of apoptosis in activated T cells [18]. It may even contribute directly to the regulation of B cell responses, since B cells express CTLA-4 after cell-cell contact with activated T cells [19]. Polymorphisms in the CTLA-4 gene have been tested for association with breast cancer in an Iranian population [12,13]. In the case-control study described here, we investigated the association between five putatively functional polymorphisms (-1661 G/A, -658 T/C, -318 T/C, +49 G/A and CT60 G/A) of the CTLA-4 gene and the risk of sporadic breast cancer in Chinese Han women.
###end p 40
###begin p 41
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 163 170 163 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 813 815 813 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 918 919 918 919 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 920 921 920 921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 992 999 992 999 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 1096 1098 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1376 1382 1376 1382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4</italic>
###xml 369 377 <span type="species:ncbi:9606">patients</span>
###xml 480 488 <span type="species:ncbi:9606">patients</span>
###xml 613 618 <span type="species:ncbi:9606">women</span>
###xml 756 764 <span type="species:ncbi:9606">patients</span>
###xml 1657 1665 <span type="species:ncbi:9606">patients</span>
A promoter region is the transcription factor binding site and regulates the level of expression of the gene [20]. This was the first study indicating that in the CTLA-4 promoter -658 CC genotype may increase breast cancer risk and -658T allele has a protective role in breast cancer. We also found that -1661 AA genotype and -318 CC genotype frequencies were lower in patients than in controls. The -1661G allele and -318T allele carrier frequencies were significantly higher in patients than in controls. These results suggest that these alleles might have an association with breast cancer risk in Chinese Han women. In contrast, there were no significant differences in genotype, allele, or haplotype frequencies in -1661 A/G and -318 C/T loci between patients and healthy controls in the Iranian population [13]. Some reports have suggested that the -318T allele may play a protective role in autoimmune disease [8,9]. The presence of the -318T allele may contribute to up regulation of CTLA-4 expression, and may therefore represent one mechanism that inhibits exaggerated immune activity [21]. Although we did not obtain the TT genotype of the -318 T/C site, our results show that T allele frequency was associated with an increased risk of breast cancer. Thus, our findings are consistent with earlier studies showing that the -318T allele increases the expression of CTLA-4, inhibits the activation of T lymphocytes and consequently limits the potency of tumor immunity. On the other hand, our results did not show an association of promoter genotypes and alleles with lymph node metastasis and tumor size at the time of diagnosis in breast cancer patients.
###end p 41
###begin p 42
###xml 17 24 17 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 140 147 140 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 179 180 179 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 197 204 197 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 986 993 986 993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 1071 1078 1071 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 1301 1303 1301 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1405 1407 1405 1407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1408 1410 1408 1410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 2030 2037 2030 2037 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 2074 2076 2074 2076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 2077 2079 2077 2079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 2193 2195 2193 2195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 599 607 <span type="species:ncbi:9606">patients</span>
###xml 917 922 <span type="species:ncbi:9606">women</span>
###xml 1372 1380 <span type="species:ncbi:9606">patients</span>
###xml 1614 1622 <span type="species:ncbi:9606">patients</span>
###xml 1769 1777 <span type="species:ncbi:9606">patients</span>
###xml 2360 2368 <span type="species:ncbi:9606">patients</span>
Among all of the CTLA-4 gene variants, the +49 G/A polymorphism is the most extensively studied, since this is the only polymorphism in the CTLA-4 gene that alters an amino acid [7]. Moreover, the CTLA-4 +49G allele has also been associated with incomplete glycosylation of the signal peptide and altered processing in the endoplasmic reticulum, which affects the CTLA-4-driven down regulation of T-cell activation and is an important factor in the pathogenesis of autoimmune diseases [16,22]. In our study, there were no significant differences in genotype or allele frequencies in +49 G/A between patients and healthy controls. However, the tumor size was significantly different between carriers of the AA and GG genotypes at position +49 G/A in comparison to other genotypes. This result suggests that +49 G/A was involved in the progression of breast cancer rather than in its initial development in Chinese Han women. The CT60 G/A polymorphism, located in 6.1-kb region 3' of the CTLA-4 gene, affects the ratio of trans-membrane to soluble mRNA splice forms of the CTLA-4 gene. Furthermore, the allele G is associated with lower levels of soluble CTLA-4 (sCTLA-4) expression. Genotypes producing higher levels of sCTLA-4 have been shown to protect against the development of autoimmune disease [23]. Many studies have reported that the CT60G allele was increased in patients of autoimmune diseases [24-26]. In our case-control study, we report for the first time that the CT60G allele shows a weak association with breast cancer, although the genotypic distributions were not significantly different between patients and controls. Our findings were in contrast to previous hypotheses proposing that alleles conferring susceptibility to autoimmunity are sparse in patients with cancer. To substantiate this result, further case-control studies of other ethnic groups are required. In addition, more studies should be carried out to clarify the exact mechanism of CT60 variant effects. In Taiwanese and Dutch populations, the CTLA-4 CT60G allele is the predominant one [24,27]. However, in our study, the CT60A allele is more prevalent than the allele G, consistent with previous reports [28]. Our study also revealed there was no association of CT60 genotypes or alleles with lymph node metastasis and tumor size at the time of diagnosis in breast cancer patients.
###end p 42
###begin p 43
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 284 285 284 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 224 232 <span type="species:ncbi:9606">patients</span>
###xml 495 500 <span type="species:ncbi:9606">women</span>
###xml 609 614 <span type="species:ncbi:9606">women</span>
###xml 670 678 <span type="species:ncbi:9606">patients</span>
###xml 834 842 <span type="species:ncbi:9606">patients</span>
Previous studies have suggested that differences in CTLA-4 function are most likely to be associated with the haplotype rather than with individual SNP [29]. The frequencies of the haplotypes, ATCGA and ATCAG, were lower in patients compared with healthy controls. However, after the P-value was corrected for multiple testing only haplotype ATCGA showed a significant difference. This result might imply a protective role for these two haplotypes in combination of breast cancer in Chinese Han women. Tsung-Hsien Su et al. reported that CGG (-318C, +49G, CT60G) was the most prevalent haplotype in Taiwanese women [30]. In this context, the most frequent haplotypes in patients and controls were ACCAG and ACCGA. However, statistical analysis did not reveal significant differences in the frequencies of these two haplotypes between patients and healthy controls. Furthermore, we found significant association of ACCAA, ACCAG and ACCGA haplotypes with tumor size, suggesting that these three haplotypes participate in the progression of breast cancer.
###end p 43
###begin title 44
Conclusion
###end title 44
###begin p 45
###xml 26 33 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 202 209 202 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 275 282 275 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
###xml 394 401 394 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA-4 </italic>
Our data suggest that the CTLA-4 gene may be involved in the susceptibility to and progression of breast cancer in the Chinese Han population. The promoter region (-1661 G/A, -658 T/C, -318 T/C) of the CTLA-4 gene may be the causal variants in breast cancer disease, whereas CTLA-4 +49 G/A may participate in the progression of breast cancer. In addition, this study also demonstrates that the CTLA-4 haplotypes, ATCGA and ATCAG, may have a protective role in breast cancer. We also show that three haplotypes, ACCAA, ACCAG and ACCGA, participate in the progression of breast cancer. Considering that the limited sample size may produce relative risk estimates lacking adequate precision, extended analyses with larger sample size should be carried out from different ethnic origins to further verify this association.
###end p 45
###begin title 46
Abbreviations
###end title 46
###begin p 47
CI, confidence interval; CTLA-4, cytotoxic T-lymphocyte antigen-4; HWE, Hardy-Weinberg equilibrium; NK, natural killer; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; sCTLA-4, soluble CTLA-4; SNP, single nucleotide polymorphism
###end p 47
###begin title 48
Competing interests
###end title 48
###begin p 49
The author(s) declare that they have no competing interests.
###end p 49
###begin title 50
Authors' contributions
###end title 50
###begin p 51
###xml 85 92 <span type="species:ncbi:9606">patient</span>
Lihong Wang performed the primer design and wrote the drafts. Dalin Li collected the patient and control blood samples. Zhenkun Fu and Heng Li performed the PCR-RFLP experiments. Wei Jiang contributed statistical analysis. Dianjun Li conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.
###end p 51
###begin title 52
Pre-publication history
###end title 52
###begin p 53
The pre-publication history for this paper can be accessed here:
###end p 53
###begin p 54

###end p 54
###begin title 55
Acknowledgements
###end title 55
###begin p 56
###xml 290 298 <span type="species:ncbi:9606">patients</span>
This work was supported by a grant from the Science Foundation of Heilongjiang province, China (GB05C402-03), the Innovative Fund of Heilongjiang Province Graduate Student (YJSCX2007-0197HLJ) and the Innovative Fund of Harbin Medical University Graduate Student (HCXB2007001). We thank all patients and healthy blood donors for providing blood samples. We are grateful for the collaboration received from the participating hospitals and their staff.
###end p 56
###begin article-title 57
CTLA-4 blockade: unveiling immune regulation
###end article-title 57
###begin article-title 58
Costimulatory wars: the tumor menace
###end article-title 58
###begin article-title 59
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
###end article-title 59
###begin article-title 60
Enhancement of antitumor immunity by CTLA-4 blockade
###end article-title 60
###begin article-title 61
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade
###end article-title 61
###begin article-title 62
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
###end article-title 62
###begin article-title 63
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
###end article-title 63
###begin article-title 64
CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms
###end article-title 64
###begin article-title 65
###xml 138 146 <span type="species:ncbi:9606">patients</span>
The common -318C/T polymorphism in the promoter region of CTLA4 gene is associated with reduced risk of ophthalmopathy in Chinese Graves' patients
###end article-title 65
###begin article-title 66
Functional evaluation of the autoimmunity-associated CTLA4 gene: the effect of the (AT) repeat in the 3'untranslated region (UTR)
###end article-title 66
###begin article-title 67
Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus
###end article-title 67
###begin article-title 68
Cytotoxic T lymphocyte antigen-4 gene in breast cancer
###end article-title 68
###begin article-title 69
Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer
###end article-title 69
###begin article-title 70
Cytotoxic T-lymphocyte antigen-4 microsatellite polymorphism is associated with multiple myeloma
###end article-title 70
###begin article-title 71
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin's lymphoma
###end article-title 71
###begin article-title 72
A common CTLA4 haplotype associated with coeliac disease
###end article-title 72
###begin article-title 73
###xml 15 20 <span type="species:ncbi:9606">human</span>
SNP alleles in human disease and evolution
###end article-title 73
###begin article-title 74
Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases
###end article-title 74
###begin article-title 75
Activated T cells can induce high levels of CTLA-4 expression on B cells
###end article-title 75
###begin article-title 76
FOXP3 controls regulatory T cell function through cooperation with NFAT
###end article-title 76
###begin article-title 77
A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein
###end article-title 77
###begin article-title 78
###xml 22 27 <span type="species:ncbi:9606">human</span>
A polymorphism in the human cytotoxic T-lymphocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell activation
###end article-title 78
###begin article-title 79
Association of the CT60 marker of the CTLA4 gene with systemic lupus erythematosus
###end article-title 79
###begin article-title 80
###xml 62 70 <span type="species:ncbi:9606">patients</span>
CTLA4 +49 A/G and CT60 polymorphisms in Dutch coeliac disease patients
###end article-title 80
###begin article-title 81
CT60 single nucleotide polymorphism of the CTLA-4 gene is associated with susceptibility to Graves' disease in the Taiwanese population
###end article-title 81
###begin article-title 82
Association of a CTLA-4 3' untranslated region (CT60) single nucleotide polymorphism with autoimmune thyroid disease in the Japanese population
###end article-title 82
###begin article-title 83
Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma
###end article-title 83
###begin article-title 84
Polymorphisms at +49A/G and CT60 sites in the 3' UTR of the CTLA-4 gene and APECED-related AIRE gene mutations analysis in sporadic idiopathic hypoparathyroidism
###end article-title 84
###begin article-title 85
Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjogren's syndrome
###end article-title 85
###begin article-title 86
###xml 34 54 <span type="species:ncbi:10566">human papillomavirus</span>
###xml 115 120 <span type="species:ncbi:9606">women</span>
CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical squamous cell carcinoma in Taiwanese women
###end article-title 86

